The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Vinai Gondi

Bridget Koontz

Priya Rastogi

Lisa Lenrow

NRG Oncology, an NCI National Clinical Trials Network group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple committees.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.
Clinical Roundup

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account